Beta-2 Microglobulin Predicts Lupus Nephritis, SLE Disease Activity
Serum beta-2 microglobulin can be used to monitor kidney damage in systemic lupus erythematosus for earlier diagnosis of lupus nephritis.
Serum beta-2 microglobulin can be used to monitor kidney damage in systemic lupus erythematosus for earlier diagnosis of lupus nephritis.
Upward trend follows debut of the federal End-Stage Renal Disease Treatment Choices payment model in January 2021.
The slow clinical adoption of sodium-glucose cotransporter-2 inhibitors may partly be due to concerns about potential adverse effects, investigators suggested.
While uncommon, BK polyomavirus-associated nephropathy is associated with a “substantial” risk of graft loss in kidney transplant recipients.
ASPREE trial data offered a “unique opportunity” to assess bleeding risk in older populations with and without CKD.
Latest findings are from a post hoc meta-analysis of pooled data from the DAPA-HF and DELIVER trials.
Guidelines support the use of RAASi at the maximum tolerated dose in patients with CKD and heart failure.
The ratio is a clinically meaningful indicator that is easily obtained from blood test results, according to investigators.
Despite a warning from the FDA Adverse Event Reporting System, studies have found that SGLT2 inhibitor use is not associated with an increased risk of AKI.
Dietary counseling may improve clinical outcomes for men with prostate cancer.